Clinical Trial Update: NeoAdjuvant Therapy With Immunoreagent (SHR-1316) for Resectable Oesophageal Squamous Cell carciNoma [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating neoadjuvant SHR-1316 immunoreagent for resectable esophageal squamous cell carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Squamous Cell Carcinoma

Drugs mentioned

• SHR-1316

Snippet

Sponsor: Shanghai Zhongshan Hospital | Conditions: Oesophageal Squamous Cell Carcinoma | Phase 2 | Status: UNKNOWN